Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma

被引：0

作者：

Martin, Thomas ^{[1
]}

Dimopoulos, Meletios-Athanasios ^{[2
]}

Mikhael, Joseph ^{[3
]}

Yong, Kwee ^{[4
]}

Capra, Marcelo ^{[5
]}

Facon, Thierry ^{[6
]}

Hajek, Roman ^{[7
,8
]}

Spicka, Ivan ^{[9
]}

Casca, France ^{[10
]}

Mace, Sandrine ^{[11
]}

Risse, Marie-Laure ^{[12
]}

Moreau, Philippe ^{[13
]}

机构：

[1] Univ Calif San Francisco, Dept Hematol, San Francisco, CA USA

[2] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece

[3] Translat Genom Res Inst, City Hope Canc Ctr, Phoenix, AZ USA

[4] Univ Coll Hosp, Dept Hematol, London, England

[5] Hosp Mae Deus, Ctr Integrado Hematol Oncol, Porto Alegre, RS, Brazil

[6] Lille Univ Hosp, Dept Hematol, Lille, France

[7] Univ Ostrava, Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic

[8] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[9] Charles Univ & Gen Hosp, Ist Fac Med, Dept Hematol, Dept Med, Prague, Czech Republic

[10] Ividata Life Sci Contracted Sanofi, Levallois Perret, France

[11] Sanofi R&D Translat Med, Chilly Mazarin, France

[12] Sanofi R&D, Vitry Sur Seine, France

[13] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

MM; IKEMA; isatuximab; multiple myeloma; progression-free survival; Phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-064

引用

页码：S403 / S404

页数：2

共 50 条

[1] Updated Progression-free Survival (PFS) and Depth of Response in IKEMA, A Randomized Phase 3 Trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma (MM)
Mikhael, Joseph
Moreau, Philippe
Dimopoulos, Meletios-Athanasios
Yong, Kwee
Capra, Marcelo
Facon, Thierry
Hajek, Roman
Spicka, Ivan
Casca, France
Mace, Sandrine
Risse, Marie-Laure
Martin, Thomas
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S37 - S38
[2] Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
Yong, Kwee
Moreau, Philippe
Dimopoulos, Meletios A.
Mikhael, Joseph
Capra, Marcelo
Facon, Thierry
Hajek, Roman
Spicka, Ivan
Casca, France
Mace, Sandrine
Risse, Marie-Laure
Martin, Thomas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S194 - S195
[3] VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
Moreau, P.
Dimopoulos, M. A. C.
Mikhael, J.
Yong, K.
Capra, M.
Facon, T.
Hajek, R.
Spicka, I.
Casca, F.
Mace, S.
Singh, E.
Risse, M-L.
Martin, T.
ANNALS OF ONCOLOGY, 2022, 33 (06) : 664 - 665
[4] Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma
Banerjee, Rahul
Lo, Mimi
Martin, Thomas G., III
FUTURE ONCOLOGY, 2021, 17 (35) : 4849 - 4860
[5] Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis
Joseph, Mikhael
Roman, Hajek
Philippe, Moreau
Bradle, Augustson
Nelson, Castro
Tomas, Pika
Sosana, Delimpasi
Javier, De la Rubia
Angelo, Maiolino
Anthony, Reiman
Joaquin, Martinez-Lopez
Thomas, Martin
Kwee, Yong
Marie-Laure, Risse
France, Casca
Sylvia, Marion
Sandrine, Mace
Meletios, A. Dimopoulos
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S12 - S12
[6] Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis
Hajek, Roman
Moreau, Philippe
Augustson, Bradley
Castro, Nelson
Pika, Tomas
Delimpasi, Sosana
De la Rubia, Javier
Maiolino, Angelo
Reiman, Anthony
Martinez-Lopez, Joaquin
Martin, Thomas
Mikhael, Joseph
Yong, Kwee
Risse, Marie-Laure
Casca, France
Marion, Sylvia
Mace, Sandrine
Dimopoulos, Meletios A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S28 - S29
[7] Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis
Martin, Thomas
Hajek, Roman
Moreau, Philippe
Augustson, Bradley
Castro, Nelson
Pika, Tomas
Delimpasi, Sosana
De la Rubia, Javier
Maiolino, Angelo
Reiman, Anthony
Martinez-Lopez, Joaquin
Mikhael, Joseph
Yong, Kwee
Risse, Marie-Laure
Casca, France
Marion, Sylvia
Mace, Sandrine
Dimopoulos, Meletios A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S411 - S412
[8] Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) In Relapsed Multiple Myeloma Patients With 1q21+Status: Updated Results From The Phase 3 IKEMA Study
Thierry, Facon
Philippe, Moreau
Ivan, Spicka
Kenshi, Suzuki
Kwee, Yong
Joseph, Mikhael
Taro, Fukao
Kamlesh, Bisht
Nicole, Armstrong
Sandrine, Mace
Marie-Laure, Risse
Thomas, Martin
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S26 - S26
[9] Isatuximab (Isa) Plus Carfilzomib (K) and Dexamethasone (d) vs Kd in Relapsed Multiple Myeloma: Interim Analysis of a Phase 3, Randomized, Open-Label Study (IKEMA)
Moreau, Philippe
Dimopoulos, Meletios-Athanasios
Mikhael, Joseph
Yong, Kwee
Capra, Marcelo
Facon, Thierry
Hajek, Roman
Spicka, Ivan
Risse, Marie-Laure
Asset, Gaelle
Mace, Sandrine
Martin, Thomas
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S22 - S22
[10] Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).
Martin, Thomas G.
Dimopoulos, Meletios A.
Yong, Kwee
Mikhael, Joseph
Risse, Marie-Laure
Asset, Gaelle
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →